Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest
Hepion Pharmaceuticals, Inc. (OTCQB:HEPA) ("Hepion" or the "Company"), a biotechnology company developing therapeutic and diagnostic candidates for areas of high unmet medical need, today reported results from an expanded modeling and simulation analysis of GV104, conducted by its wholly-owned subsidiary Gravitas Life Sciences, LLC ("GLS"), and the written feedback received from the U.S. Food and Drug Administration ("FDA" or "Agency"). The...
Read more








